Hansa Biopharma’s BLA for imlifidase accepted by the FDA

The investment supports the continued development and scaling of the company’s antibody technology platforms, enabling expanded application areas and strengthened industry collaborations.

Beactica Therapeutics, together with glioblastoma researchers at KU Leuven, has been awarded the grant to advance a precision immune therapy for glioblastoma.

The funding comprises a EUR 2 million non-dilutive grant from the European Innovation Council (EIC) Transition program and EUR 3.9 million in private capital and convertibles from Voima Ventures, Nordic Science Investments (NSI), Illumina Ventures, Almi invest, Life Science Invest and several undisclosed private investors from the genomics technology space.

Suzhou Ribo Life Science and its Swedish subsidiary Ribocure Pharmaceuticals have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

The financing round was led by Sciety and the capital will be used to advance the company’s ongoing clinical study and to build the data required for the next stage of its development programme.

Medivir has completed a directed share issue of SEK 45 million (before issue costs) to Carl Bennet AB, issuing 90 million new shares at SEK 0.50 per share—a 19 percent premium to the closing price on February 5, 2026.

Cereno Scientific is broadening the development focus of its HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD).